Stem Cell in Acute Myocardial Infarction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2022

Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL

Mesenchymal Stem Cells

The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.

Trial Locations (1)

Unknown

PT Prodia StemCell Indonesia, Jakarta

All Listed Sponsors
lead

PT. Prodia Stem Cell Indonesia

INDUSTRY

NCT04340609 - Stem Cell in Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter